We also showed that MDSC miR-126a rescues DOX-induced MDSC death in a S100A8/A9-dependent manner and promotes tumor angiogenesis. Our findings provide insight into the MDSC exosomal-mediated chemoresistance mechanism, which will be useful for the design of inhibitors targeting the blocking of induction of miR-126a + MDSCs.
INTRODUCTION
Although chemotherapy/radiation therapy is one of the most common treatments for cancer patients, chemotherapy fails to kill all cancer cells because of intrinsic or acquired drug resistance. Acquired resistance accounts for 490% of unsuccessful treatments in advanced cancer patients. Chemotherapy/radiation therapy induces inflammation by activation of a number of inflammatory cells, including myeloid-derived suppressor cells (MDSCs), 1 IL-13 + Th2 cells 2, 3 and endothelial cells (ECs). 4 Inflammation activates a number of pathways that contribute to the chemoresistance. 5 Therefore, there is a dire need for understanding the inflammation-associated cellular and molecular pathways leading to chemoresistance and further development of novel strategies to block/reverse chemoresistance would also yield a new and practical therapeutic method for treatment of cancer patients.
MDSCs are a heterogenic and immunosuppressive subset of cells that promote tumor vasculogenesis and tumor progression. Recent findings reported that chemotherapy induces MDSCs, resulting in attenuation of the anticancer efficacy of the chemotherapy. 6, 7 Chemotherapy also causes an increase in MDSC numbers in breast cancer patients 8, 9 and melanoma 10, 11 and enhances immunosuppression. Blocking MDSC actions reverses docetaxel chemoresistance in a mouse model of prostate cancer. 12 How MDSCs mediate development of chemoresistance is not well studied.
Exosome-mediated drug resistance has been identified across a broad spectrum of tumors. [13] [14] [15] [16] [17] Despite a growing number of studies demonstrating that MDSC-released exosomes have a role in immune suppression, 18 it is unknown whether the exosomes released from chemotherapeutic drug-treated versus non-treated MDSCs have different biological activities in terms of regulating tumor progression and chemoresistance. More specifically, understanding whether MDSC exosomes facilitate the development of chemotherapy resistance via remodeling host immune responses is needed for further elucidating the role of chemodrug-induced MDSC exosomes in disease progression, metastasis and response to treatment.
One of the mechanisms underlying tumor exosome-mediated drug resistance and tumor immune escape is likely to the exporting of harmful factors from tumor cells to immune cells. Exosomes are enriched with non-coding RNA, including microRNA (miRNA). miRNAs are a class of small, non-coding RNAs that posttranscriptionally control the translation and stability of mRNAs. Hundreds of miRNAs are known to have dysregulated expression in cancer. [19] [20] [21] miRNAs could act as tumor suppressors or oncogenes depending on the interactions of mRNA and various factors. In this study, we investigated the role of MDSC exosomal miR-126a on lung metastasis of the murine breast tumor as exosomal miR-126a released from MDSCs is enriched upon doxorubicin (DOX) treatment. miR-126a has been shown to be both a tumor suppressor and an oncogene depending on the type of cancer studied. 22 Overexpression of miR-126a in tumor cells inhibits tumor growth through the inhibition of expression of genes related to tumor cell cycles. 23 miR-126a also supports cancer progression 24, 25 through the promotion of blood vessel formation [26] [27] [28] and inflammation 29 at the site of activation of other types of cancer. High miR-126 expression in acute myeloid leukemia was associated with poor survival and higher chance of relapse. 24 The cellular and molecular mechanisms underlying these discrepancies in terms of response to miR-126a are not known. The role of chemotherapy-induced miR-126a in MDSCs in terms of tumor progression and subsequent biological effect of miR-126a delivered by MDSC exosomes on the recipient cells has not been studied, although it was reported that miR-126 controls the survival and function of plasmacytoid dendritic cells. 28 It is known that T helper type 2 (Th2) polarization of tumor microenvironments via type 2 cytokines promotes tumor metastasis and contributes to chemoresistance. Inflammation-induced miR-126 accelerates the development of allergic airways disease through induction of Th2 T cells. 30 Recent studies show that induction of the production of interleukin (IL)-33 by chemotherapeutic agents is crucial for the induction of type 2 immune responses by promoting the synthesis of cytokines, such as IL-13. 31 ,32 IL-33-driven Th2 cells are rapid and potent producers of the type 2 cytokine IL-13 33, 34 and may contribute to carcinogenesis. Exosomes have been known to have a crucial role in intercellular communication. Whether MDSC-derived exosomes have a role in induction of chemoresistance through cross-talking with IL-13 + Th2 T cells is not known. Furthermore, whether exosome-mediated MDSC-IL-13 + Th2 cell interactions contribute to chemoresistance is an entirely novel topic.
Although tumor-derived exosomes are emerging as mediators of tumorigenesis, the role of MDSC-derived exosomes has not been fully understood. In this study, using the murine breast cancer model as a proof of concept, we tested the hypothesis that exporting miR-126a via MDSC exosomes is one of the important mechanisms underlying chemoresistance. We explored the function of MDSC-derived exosomes in metastasis in mice. MDSC exosomes from highly metastatic breast tumor increased the metastatic behavior of primary tumors by permanently crosstalking with Th2 T cells and ECs through MDSC exosomal miR-126a. Anti-miR-126a therapy decreased DOX treatmentinduced resistance and reduced tumor growth and metastasis. In addition, we identified that MDSC-derived exosomes also prevent DOX-induced MDSC death by upregulating the expression of S100A8/A9. Our data show that MDSC exosomes induced by DOX treatment supports metastasis, has prognostic value and offers promise for new therapeutic directions in the metastatic process.
RESULTS DOX treatment induces MDSC through an IL-33/IL-13-mediated pathway in metastatic lung lesions Given that proinflammatory cytokines have been associated with the severity of chemotherapy-induced mucositis, 31 we hypothesize that pulmonary toxicity caused by DOX may result in an immune-mediated hypersensitivity reaction. To test this hypothesis, 4T1 breast tumor-bearing mice were treated with DOX (5 mg/kg) at 15 days posttumor implantation. We observed the production of IL-33 and that its soluble receptor sST2 was significantly elevated in lung tissue extracts from 4T1 tumorbearing mice systemically treated with DOX as compared with that of the vehicle-treated control (VEH) mice (Figure 1a) . Immunohistochemistry staining confirmed that IL-33 was most prominently detected in DOX-treated lung epithelial cells in the lung (Figure 1b) . IL-33/ST2 is crucial for the induction of type 2 immune responses by promoting the synthesis of cytokines such as IL-13 by Th2 lymphocytes. 35, 36 After DOX treatment, we found that infiltration of lung by IL-4 + IL-13 + CD4 + Th2 cells was increased significantly (Figures 1c and d ) in addition to Th1 and Th17 T-cell increases reported by others 6 (Supplementary Figure S1A) . The results were also repeated in the C57BL/6-mouse-derived E0771 model of spontaneously metastatic mammary cancer and CT-26 colon cancer model (Supplementary Figures S2A-F) . GATA3 is one of the crucial molecules that induce Th2 cells while suppressing  their differentiation toward Th1 cells. CD4  + T lymphocytes isolated  from DOX-treated mice exhibited elevated expression of GATA-3  mRNA and the percentages of GATA3  + CD4  + T cells and STAT6   +   CD4  + T cells (Supplementary Figures S1B and C) , when compared with vehicle-treated mice. Collectively, those data indicate that Th2 effector lineage was expanded in the lung of tumor-bearing mice in response to DOX treatment.
We also found that DOX treatment increased the levels of chemokines, including C-X-C motif chemokine ligand 1/2 (CXCL1/2) and C-C motif chemokine ligand 2 (CCL2), in mice (Supplementary Figure S1D) compared with mice treated with phosphate-buffered saline (PBS) as a control. CXCL1/2 and CCL2 have a role in recruitment of immature myeloid cells (CD11b + Gr-1 + ) to sites of inflammation. In agreement with data published by others, 37 a reduction in the proportion and the number of MDSCs in the spleen of DOX-treated tumor-bearing mice was observed. However, in contrast to MDSCs in the spleen, the proportion of MDSCs was significantly increased in the lungs of treated mice when compared with the untreated mice ( Figure 1e ). The data generated from real-time PCR (RT-PCR) analysis further indicate that DOX increased the expression of the immunosuppression genes encoding for arginase 1 (Arg1) and transforming growth factor-β and decreased genes encoding for inducible nitric oxide synthase 2 (Nos2) and tumor necrosis factor-α (TNF-α) in the lung of MDSC tumor-bearing mice when compared with mice treated with PBS (Supplementary Figure S3A) . Most notable was the detection of S100A8/9, known to have a role in promoting tumor lung metastasis, 38 which was expressed in abundance in DOX-induced CD11b 
Gr1
+ cells (Supplementary Figure S3A) . Induction of DOX-treated MDSCs is associated with increased expression of IL-13alpha1R (Supplementary Figure S3A) . Therefore, DOX treatment might lead to induction of Arg1 and S100A9 in MDSCs via IL-13. To address this, we assessed the ability of IL-13 to induce the expression of Arg1 and S100A9 in MDSCs in vivo and in vitro. IL-13 alone significantly induced Arg1 expression in MDSCs compared with vehicle-treated MDSCs (Figure 1f ), whereas the expression of NOS2 was suppressed. Interestingly, IL-13-induced Arg1 and S100A9 expression was enhanced significantly by the presence of IL-33, which expands functional MDSCs. However, DOX in combination with IL-13, IL-33 or both had no additional effect on the induction of Arg1 and S100A9 expression compared with IL-13, IL-13 or both (Figure 1f ). To determine whether IL-13 produced by CD4 + T cells is involved in inhibition of the M1 cytokine profile, mainly IL-12 and TNF-α, primary MDSC or interferon (IFN)-γ/lipopolysaccharide-stimulated MDSCs were co-cultured with lung CD4 cells isolated from vehicle-and DOX-treated tumor-bearing mice. We found that addition of DOX-treated CD4 + T cells reduced the secretion of TNF-α and IL-12 more than addition of vehicle-treated CD4 + T cells (Figure 1g ). This effect was reversed in the presence of anti-IL-13 antibody (Figure 1g ), indicating that CD4 + T lymphocytes isolated from DOX-treated tumor-bearing mice inhibit the production of IL-12 and TNF-α via an IL-13-mediated signaling pathway. Figure S3B) . We further confirmed the array-based CXCL1 result with a standard enzyme-linked immunosorbent assay (ELISA; Supplementary Figure S3C ).
As IL-4 + IL-13 + CD4 + Th2 cells were increased significantly, we decided to determine whether T cells have a role in the MDSCmediated tumor progression using Rag1 − / − mice. In contrast to DOX-MDSC isolated from wild-type 4T1 tumor-bearing mice, DOX-MDSC from Rag1 − / − mice, which lack T cells, have lost the capacity to promote tumor progression (Figures 2a and b) .
Exosomes released from DOX-MDSC enhance Th2 cell responses and tumor angiogenesis in the lung of tumor-bearing mice Given the fact that DOX-MDSCs have a role in promoting tumor progression via an interaction with CD4 + T cells and ECs, and because cytokines and exosomes are known to be released from MDSCs and have a role in intercellular communications, 42, 43 we further tested whether exosomes released from DOX-MDSCs have a role in the induction of new blood vessels and suppression Figure S4) . To test whether DOX-MDSC-derived exosomes contribute to the induction of Th2 cell responses in vitro, CD4 + T cells from OT-II transgenic mice were used. MDSC-derived exosomes were mixed with OT-II splenocytes in the presence of control or OT-II-specific peptides, and cytokine production was evaluated. DOX-MDSCderived exosomes displayed a potent ability to inhibit T-cell proliferation (Figure 3d) . Furthermore, the addition of DOX-MDSCderived exosomes significantly promoted the production of IL-4 and IL-13 (Figures 3e and f) . Collectively, these data indicate that MDSC-derived exosomes contribute to MDSC-mediated suppression of Th1 cell activation and DOX treatment enhanced the MDSC-derived exosomal suppression of T-cell activity, tumor angiogenesis and induced Th2 cell responses in the lung of tumorbearing mice.
Induction of MDSC exosomal miR-126a is regulated by DOX treatment To further explore the molecular mechanisms underlying DOXexosome mediated induction of Th2 cell responses, we first performed a miRNA microarray analysis of MDSC exosomes. Total exosomal RNA from DOX-MDSCs and VEH-MDSCs were extracted and miRNA expression profiling was performed. Among the exosomal miRNAs analyzed, 11 miRNAs from DOX-MDSCs were significantly altered compared with the VEH-MDSCs (significant at 0.01 level of the univariate test; Supplementary Figure S5A ). We then focused on miRNAs that could potentially function as tumor angiogenesis factors and induce Th2 cell responses. Within the three most expressed miRs in the exosome microRNA profile, the level of miR-126a was much higher in DOX-MDSC exosomes than in VEH-MDSC exosomes (Supplementary Figure S5A) . The results were confirmed by RT-PCR (Supplementary Figure S5B) . In addition, the treatment of ex vivo cultured lung MDSCs with DOX led to induction of miR-126a in MDSCs and its derived exosomes (Supplementary Figure S5C) . The treatment of MDSCs with GW4869, which was reported to inhibit the secretion of exosome from cells, 44, 45 resulted in reduction of miR-126a secreted in the exosomes of the DOX-treated MDSCs (Supplementary Figure S5D) . To determine whether miR126a is actively sorted into the exosomes, we transfected DOX-MDSCs with miR-126a hairpin inhibitors, miR-126a mimic or a control inhibitor (scramble RNA, named mock) with a nanovector made of grapefruit-derived lipids. 46 An miR-126a inhibitor treatment significantly reduced miR-126a expressed in MDSCs and in MDSC-derived exosomes (Supplementary Figure S6A) , whereas transfection of miR126 mimic led to an increase in miR-126a encapsulated in the exosomes (Supplementary Figure S6B) , suggesting that miR-126a is sorted into exosomes. Together, these data support that DOX induces miR-126a expression in MDSCs and subsequently is released from MDSCs via the exosomal biogenesis pathway.
To test whether MDSC miR-126a is transferred to ECs/CD4 T cells, MDSCs were transfected with fluorescent-labeled miR-126 mimics, washed and then co-cultured with ECs or CD4 T cells in a transwell assay. We observed after an overnight incubation that the fluorescent-labeled miR-126a was transferred to the ECs (Supplementary Figure S7A) or CD4 T cells (Supplementary Figure S7B) . We then examined whether DOX-induced miR-126a in MDSCs or MDSC-derived exosomes contribute to the induction of Th2 cell responses and angiogenesis in vitro. Transfection of Th2-cell-polarized T cells with miR-126a mimic increased the expression of miR-126a and enhanced the secretion of IL-4 and IL-13 ( Figure 4a ). In contrast, transfection of Th1-cell-polarized T cells with miR-126a mimic decreased the secretion of IFN-γ (Figure 4b ). These observations suggest that the transfer of miR-126a from MDSCs to T cells may be an important intermediary step for the induction of Th2 cells. To further test whether DOX-induced MDSC exosomes contribute to the suppression of Th1 cell responses, we co-cultured VEH-MDSC-or DOX-MDSCderived exosomes with Th1 cells. The result of ELISA analysis indicated that DOX-MDSC-derived exosomes significantly suppress the induction of IFN-γ, whereas exosomes from miR-126a inhibitor-transfected MDSCs had lost their ability to suppress induction of IFN-γ (Figure 4c ). We further examined the effects of exosomes derived from miR-126a inhibitor-transfected and miR-126a mimic-transfected MDSCs on tube formation in vitro. Exosomes derived from miR-126a mimic-transfected MDSCs had an enhanced effect on tube formation (Figure 4d ), whereas exosomes from miR-126a inhibitor-transfected MDSCs had a substantially reduced effect on tube formation (Figure 4d ). These data indicate that DOX-induced exosomal miR-126a contributes to MDSC-exosome-mediated induction of Th2 T cells, prompting angiogenesis.
miR-126a-S100A8/9 axis is regulated by DOX-induced IL-33/IL-13 Our data showed that IL-33 was induced in lung tissue upon DOX treatment. To determine the effect of DOX-induced IL-33/IL-13 on miRNA expression in MDSCs, we exposed lung MDSCs from naive mice to IL-13 and/or IL-33 for 4 days in culture. Notably, the expression of miR-126a is significantly induced in MDSCs by IL-13 and/or IL-33 ( Figure 5a ). To examine the role of IL-13/IL-33-induced miR-126a in promoting MDSC accumulation and/or activation, lung MDSCs from 4T1 tumor-bearing mice were transfected with miR-126a encapsulated in a grapefruit exosome-like nanovector. 46 RT-PCR results suggest that the expression of Arg1, S100A8 and S100A9 were increased owing to miR-126a transfection (Supplementary Figure S8) . Conversely, lung MDSCs from 4T1 tumor-bearing mice transfected with miR-126a inhibitor have a decreased expression of S100A8 and S100A9 (Supplementary Figure S8) . High levels of S100A8/9 in CD11b + Gr1 + myeloid cells have been reported to be correlated with lung metastases in patients with breast cancer. 38 Importantly, MDSC-derived S100A8/9 can enhance cancer cell survival, which might be linked to chemoresistance. Indeed, when naive MDSCs were exposed to DOX for 48 h, exosomes from the miR-126a-transfected cells increased the survival of MDSC response to DOX treatment compared with exosomes from cells transfected with scramble miRNA (Figure 5b ). The role of miR-126a in rescuing MDSCs from death was further supported by the fact that exosomes from MDSCs transfected with miR-126a inhibitor induced more MDSC death (Figure 5b ). These data indicate that DOX-induced miR-126a may also have a role in regulating survival pathway(s) in MDSCs. To determine whether the observed miR-126a-mediated upregulation of S100A8 and S100A9 was associated with MDSC accumulation, we generated MDSCs that overexpressed miR-126a with/without knockdown of S100A8, S100A9 or both (S100A8/9) and evaluated differentiation of myeloid cells in the presence of granulocyte-macrophages colony-stimulating factor (GM-CSF). Overexpression of miR-126a significantly reduced the differentiation of DCs and substantially increased the production of Gr-1 + CD11b + MDSCs compared with control ( Figure 5c ). In contrast, knockdown of S100A9 did appreciably prevent the inhibition of the differentiation and survival of myeloid cells with overexpression of miR-126a (Figures 5c and d) . Collectively, these data suggest that S100A9 is one of the miR-126a-regulated genes in terms of regulation of MDSC differentiation and survival.
Systemic delivery of miR-126a inhibitor enhances DOX therapeutic effect on antilung metastasis We have recently developed grapefruit-derived nanovectors (GNVs) capable of encapsulating small interfering RNAs. 46 To address whether this edible plant-derived nanovector could be used to target MDSCs in tumor models, 4T1 tumor-bearing mice were administered intravenously (i.v.) PKH26-labeled GNVs carrying miR-126a. Twelve hours after administration, we observed the monocytic MDSCs (CD11b +
Ly6G
− Ly6C + ) in the blood (15.9), lung (14.9), spleen (13.6) and liver (21.6) were GNV + by flow cytometry (Supplementary Figure S9) . These data indicate that GNVs delivered miRNA efficiently to local and systemic MDSCs in vivo.
We next investigated the effects of miR-126a delivery on lung metastasis in breast tumor development. 4T1 tumor-bearing mice were i.v. injected with GNVs, GNVs carrying miR-126a inhibitor or GNVs carrying miR-126a mimic at a dose of 1.5 mg/kg twice each week for 4 weeks. miR-126a inhibitor in combination with DOX treatment resulted in a modest decrease in mammary tumor volume compared with DOX-and GNV-treated control mice (Figure 6a) . However, the number of metastases induced by tumor cells was very low in mice injected with GNV-miR-126a inhibitor; whereas a significant increase in the number of metastatic nodules in the lungs was observed in mice treated with GNVmiR-126a mimic (Figures 6b and c) .
To evaluate whether the administration of GNV-miR-126a inhibitor or mimic modified the lung microenvironment, the expression of vascular endothelial growth factor (VEGF), MMP-9 and MMP-2 was studied. The enhanced expression of MMP-9 and VEGF in the lung after treatment with GNV-miR-126a-mimic was evident by immunohistochemistry (Figure 6d ). Quantitative RT-PCR further confirmed that GNV-miR-126a inhibitor, but not mimic, significantly decreased VEGF, MMP-2 and MMP-9 expression in total lung tissue (Supplementary Figure S10A) . Furthermore, the proangiogenetic effect of GNV-miR-126a mimic was significantly greater in vivo than that of GNV-miR-126a inhibitor (Figure 6d) . Together, these results provide compelling evidence that delivery of GNV-miR-126a inhibitor suppresses lung metastasis during breast tumor development by reducing local vascular growth after DOX treatment.
FACS analysis of the predominant myeloid subtypes infiltrating the lung revealed that, in combination with GNV-miR-126a inhibitor, the recruitment of CD45 +
CD11b
+ Gr-1 + F4/80 − MDSCs was significantly decreased following treatment with DOX ( Figure 6e ). These results were also supported by the fact that the frequency of CD45 + CD11b + Gr-1 + F4/80 − MDSCs was significantly increased in DOX plus GNV-miR-126a mimic-treated animals ( Figure 6e ). However, analysis of myeloid subtypes remaining in tumor tissue following GNV-miR-126a inhibitor or GNV-miR-126a mimic treatment revealed no significant change in CD80, CD86 or major histocompatibility complex II expression (data not shown). In DOX-treated mice, delivery of GNV-miR-126a inhibitor suppressed the secretion of IL-4 and IL-13 from lung Th2 cells (Figure 6f) , with no effect on infiltration of natural killer cells, T regulatory cells or CD8 + T cells (data not shown). In contrast, treatment with GNV-miR-126a mimic significantly promoted DOXinduced lung Th2 cell responses when compared with those treated with GNVs (Figure 6f ). The fact that miR-126a promotes Th2 cell responses and inhibits Th1 cell induction is further supported by FACS analysis data, indicating that GNV-miR-126a inhibitor treatment showed increased expression of T-bet and decreased expression of GATA3 (Supplementary Figure S10B) .
DISCUSSION
MDSCs have emerged as immunosuppressive-associated cells and are increasingly associated with disease aggressiveness, poor prognosis, drug resistance and metastasis. In this study, we determined the metastatic effects of exosomes released from MDSCs in DOX-treated mice and investigated the mechanisms mediating these effects. Although DOX treatment was largely efficacious in inhibiting primary tumors, it significantly increased the incidence and burden of pulmonary metastasis by miR-126a + MDSC exosomes. Induction of miR-126a + MDSC exosomes by DOX strongly increased the expression of inflammatory cytokine IL-13, which is released from Th2 cells in the lungs. These proinflammatory changes promoted the outgrowth of both MDSCs and Th2 cells in the lung where they increased blood vessel formation and promote lung metastasis of breast cancer via MDSC exosomal miR-126a. These results suggest that DOX therapy of cancer patients may activate inflammatory circuits that promote angiogenesis and metastasis at premetastatic niches where invasion occurs in distant organs through induction by miR-126a + MDSC exosomes. Taken together, our findings suggest that efforts to target miR-126a + MDSC exosome production and/or the exosomal releasing pathway may simultaneously quell inflammatory pathways that promote malignant progression, with implications for how to prevent tumor recurrence and the establishment of metastatic lesions, either during chemotherapy or after it is completed.
In this study, the finding that DOX-induced exosomal miR-126a contributes to developing DOX therapy resistance provides a foundation for further identifying the molecular pathway(s) underlying how DOX induces miR-126a through IL-13 receptor expression on MDSCs and molecules targeted by exosomal miR-126a on the MDSC exosome-recipient cells. Furthermore, the results show that anti-miR-126a therapy as demonstrated in this study prevents chemotherapy resistance by targeting MDSCs, implying that this strategy could be beneficial for treatment of cancer patients in combination with chemotherapy.
In addition, finding that an increase in miR-126a + MDSC exosomes is associated with chemotherapy resistance could be utilized to predict whether DOX should be used for treatment. 
-test).
It is anticipated that circulating miR-126a + MDSC exosomes in plasma and/or serum are high in the cancer patients who are intrinsically resistant or acquired resistant to DOX treatment. Therefore, this finding has potential utility as diagnostic, prognostic and predictive biomarkers for determining chemotherapy susceptibility.
As summarized in Supplementary Figure S11 , we propose a new mechanism that promotes lung metastatic progression through the crosstalk between MDSC-derived exosomes, Th2 cells and ECs. Our data identify MDSC exosome-mediated transfer of the miR-126a as a key regulator of activation of Th2 cells and ECs and metastatic progression.
In this study, we used an antisense of miR126a approach to specifically block the effect of miR126a. Myeloid-specific miR126 knockout mice could be used to address this issue; however, these mice are not commercially available. However, one would need to be cautious because knockout of myeloid miR126a may have unpredictable effects on the myeloid cells, from development, differentiation to maturation of myeloid cells. Proteins encoded by these mRNAs may have a role in sorting the factors that regulate the functions of Th2 T cells and ECs into MDSC exosomes.
It is well known that immune cell-derived exosomes also communicate with tumor cells. In this study, we show that MDSCs communicated with T cells and ECs through MDSC exosomes. This finding provides a foundation for future studies to determine whether MDSC exosome miR-126a induced by DOX has an effect on cancer cells and contributes to the cancer cells developing chemoresistance.
Our result show that, among of MDSC exosome miRNAs, miR126a is one of the miRNAs induced by DOX treatment and one of the most enriched miRNAs in MDSC exosomes. Some published 47 data suggest that miRNAs are not randomly incorporated into exosomes. These studies show that parent cells possess a sorting mechanism that guides specific intracellular miRNAs to enter exosomes. Although the mechanisms underlying sorting miRNA into exosomes remains largely unclear, some of the cellular machineries involved in this sorting are: sphingomyelinase 2 (nSMase2) dependent; 48 the miRNA motif and sumoylated heterogeneous nuclear ribonucleoproteins (hnRNPs)-dependent pathway; 49 and the 3′-end of the miRNA sequence-dependent pathway. 50 It is well known that mature miRNAs can interact with assembly proteins to form a complex called miRISC. The main components of miRISC include miRNA, miRNA-repressible mRNA, GW182 and AGO2. Recent studies recognized a possible correlation between AGO2 and exosomal miRNA sorting. Knockout of AGO2 could decrease the types or abundance of the preferentially exported miRNAs in exosomes. 51 In summary, specific sequences present in certain miRNAs may guide their incorporation into exosomes, whereas some enzymes or other proteins may control sorting of exosomal miRNAs as well, in a miRNA sequence-independent fashion. Yet to be determined is whether Dox-induced proteins are involved in sorting miR126a into MDSC exosomes. Identification of such proteins could open up new avenue for developing therapeutic strategies for reversing MDSC exosome-mediated immunotherapy.
MATERIALS AND METHODS

Animals and treatments
C57BL/6J and OT-II mice in a C57BL/6 background and BALB/c, Rag1
mice in a BALB/c background were obtained from Jackson Laboratories (Bar Harbor, ME, USA). All animal procedures were approved by the University of Louisville Institutional Animal Care and Use Committee.
Reagents, antibodies and flow cytometry Mouse miR-126a mimic (catalogue no. MI0000153) and miR-126a inhibitor (antisense of miR126a, 5′-CGCGUACCAAAAGUAAUAAUG-3′) were purchased from Dharmacon (Lafayette, CO, USA). DOX, paclitaxel and 5-fluorouracil were purchased from Sigma-Aldrich (St Louis, MO, USA). Recombinant murine IL-33 (rmIL-33) was obtained from Biolegend (San Diego, CA, USA). Mouse IL-33 mAb (Clone 396118) and isotype control were purchased from R&D Systems (Minneapolis, MN, USA). For analysis of surface markers, cells were stained in PBS containing 2% (wt/vol) bovine serum albumin. Intracellular staining of the transcription factors Foxp3 was performed using the Foxp3 Fix/Perm Buffer Set (eBioscience, San Diego, CA, USA). For detection of intracellular cytokines, cells were first stimulated for 4 h with 50 ng/ml phorbol 12-myristate 13-acetate (PMA) and 1 μg/ml ionomycin in the presence of Brefeldin A (5 μg/ml; all obtained from Sigma-Aldrich), followed by staining for surface markers. Cells were then fixed and permeabilized using the Foxp3 Fix/Perm Buffer Set (eBioscience) and stained for intracellular cytokines. The following antibodies were used at a dilution of 1/200-1/600: PerCP-Cy5.5, phycoerythrin (PE)-, fluorescein isothiocyanate (FITC)-or allophycocyanin (APC)-labeled anti-IL-13 (eBio13A, eBioscience), PE-or APC-labeled anti-IL-4 (11B11, eBioscience), APCor PE-Cy7-labeled anti-IFN (XMG1.2), PE-labeled anti-Foxp3 (FJK-16s, eBioscience), PE-, FITC-or APC-labeled anti-CD11b (M1/70), PE-, FITC-or APC-labeled anti-CD4 (RM4-5), PE-Cy7-labeled anti-CD3 (145-2C11), FITC-, PerCP-Cy5.5 or Pacific Blue-labeled anti-CD45 (30-F11), PE-anti-Gr-1 (RB6-8C5), and PE-or FITC-labeled anti-mouse Ly6G (1A8). All antibodies were obtained from Biolegend, unless otherwise noted. Flow cytometric data were acquired on a 5-color FACScan (Becton Dickinson, Franklin Lakes, NJ, USA) and analyzed using the FlowJo software (TreeStar, Ashland, OR, USA). Cell sorting was performed using a FACSAria II.
Histology and immunohistochemistry
Tissue specimens were fixed in 10% formalin, dehydrated and then embedded in paraffin. Tissue samples were cut at 5-μm thicknesses and stained with hematoxylin and eosin. For immunofluorescence analysis, tissue sections were subjected to antigen retrieval by boiling the slides in Antigen Unmasking Solution (Vector Laboratories, Burlingame, CA, USA) for 10 min according to instructions. Sections were then blocked for 1 h at 22°C with 5% bovine serum albumin in PBS and incubated overnight at 4°C with the primary antibodies, that is, rabbit polyclonal VEGF and MMP-9 from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA) used at a dilution of 1/50, and mouse monoclonal anti-E-cadherin, anti-vimentin, CD31 and CD11b were purchased from BD Biosciences (San Jose, CA, USA) and used at a dilution of 1/100. Primary antibodies were detected by Alexa Fluor 488, 594 or 647 conjugated goat anti-mouse, anti-rabbit IgG and anti-rat (1:600, Invitrogen, Carlsbad, CA, USA). Tissues were counterstained with DAPI (4,6-diamidino-2-phenylindole), and images were captured on a Zeiss LSM 510 confocal microscope equipped with a digital image analysis system (Pixera, Santa Clara, CA, USA). For immunofluorescence analysis of macrophages, OCT (Sakura Finetek, Torrance, CA, USA)-embedded tissue cryosections (9-μm thick) were stained with F4/80 (BM8, eBioscience).
RNA extraction and PCR
Total RNA was isolated from the lung, liver and spleen lymphocytes or 4T1 tumor cells using the Qiagen (Valencia, CA, USA) RNeasy RNA isolation Kit and was used to synthesize cDNA. RNA (1 μg) was reverse-transcribed with Superscript III and random primers (Invitrogen). For quantitation of genes of interest, cDNA samples were amplified in a CFX96 Realtime System (BioRad Laboratories, Hercules, CA, USA) and SYBR Green Master Mix (Invitrogen) and specific primers (Supplementary Table S1 ) according to the manufacturers' instructions. Fold changes in mRNA expression between treatments and controls were determined by the δCT method as described. 52 Differences between groups were determined using a twosided Student's t-test and one-way analysis of variance. Error bars on plots represent ± s.e.m., unless otherwise noted. The data were normalized to a GAPDH (glyceraldehyde 3-phosphate dehydrogenase) reference. All primers were purchased from Eurofins MWG Operon (Louisville, KY, USA).
Enzyme-linked immunosorbent assay
The quantity of IL-4, IL-33, sST2, IL-13, IFN-γ (eBioscience), CXCL1, CXCL2 and CCL2 (R&D Systems) were determined in culture supernatants, serum and tissue using ELISA kits according to the manufacturer's instructions. The sensitivity of the assay was o20 pg/ml.
Cells and cell culture conditions
Breast cancer cell lines 4T1, E0771 an MDA-MB-231 and the murine EC line 2H11 were purchased from ATCC (Manassas, VA, USA) and maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 100 U/ml penicillin/streptomycin. All cells were grown in a humidified atmosphere of 5% CO 2 at 37°C.
For MDSC and MDSC-derived exosome-mediated Th1/Th2 proliferation and differentiation, naive CD4 + CD25 − CD62L + T lymphocytes were cultured for 5 days with anti-CD3 (5 μg/ml, 2C11, Bio X cell, West Lebanon, NH, USA), anti-CD28 (2 μg/ml, 37.51; Bio X Cell), IL-2 (10 ng/ml), anti-IL-4 (10 μg/ml, for Th1) or anti-IFN-γ (10 μg/ml, for Th2) in the presence of exosomes (50 μg/ml), followed by stimulation with PMA and ionomycin in the presence of brefeldin A (10 μg/ml, Sigma-Aldrich). Intracellular cytokine production on CD4 + T cells was determined by flow cytometry. For MDSC-T cell co-cultures, 5 × 10 5 MDSCs and 2.5 × 10 5 OT-II T cells were mixed in the presence of cognate peptide (5 μg/ml; ovalbumin) and/or exosomes (50 μg/ml). After 4 days of culture, live T cells were collected and stimulated with PMA (50 ng/ml) and ionomycin (1 μg/ml, Sigma-Aldrich) plus brefeldin A (10 μg/ml, Sigma-Aldrich) for intracellular cytokine staining or for mRNA analysis. mRNA were assessed by RT-PCR and supernatants were used for cytokine measurement by ELISA.
MDSC survival assay
To address MDSC survival, 1 × 10 6 MDSCs were plated in a 12-well plate. Cells were untreated, treated with 20 nM DOX in the presence of exosomes derived from MDSCs transfected with 100 nM miR-126a inhibitor (antisense of miR126a), 100 nM mimic or mock (scramble miRNA). Viability and cell number were determined by propidium iodide exclusion or with Calcein Dyes (eBioscience) for staining live cells.
Exosomes isolation
For preparation of tumor exosomes, 4T1 cells was cultured in vitro at 37°C in a humidified 5% CO 2 atmosphere in air in complete medium (DMEM with 5% fetal calf serum that had been ultracentrifuged for 16 h at 100 000 g to exclude bovine exosomes). The exosomes were purified from the supernatants by differential centrifugation. In brief, cells were removed by centrifugation for 10 min at 300 g. Supernatants were collected and centrifuged sequentially twice for 10 min at 500 g, once for 15 min at 2 000 g, once for 30 min at 10 000 g and once for 60 min at 100 000 g. Pelleted exosomes were resuspended in 5 ml of 2.6 M sucrose and 20 mM Tris-HCl (pH 7.2) and floated into an overlaid linear sucrose gradient (2.0-0.25 M sucrose, 20 mM Tris-HCl (pH 7.2)) in an SW41 tube for 16 h at 270 000 g. For preparation of MDSC exosomes, CD11b + Gr-1 + MDSCs were sorted by FACS from the spleen, lung or tumor and cultured for 3 days in the presence of 1 ng/ml GM-CSF. The supernatants containing the exosomes produced by MDSCs were then harvested. Cell supernatant was centrifuged at 300 g for 10 min. Cell-free supernatant was further centrifuged at 2 000 g and then at 10 000 g to remove dead cells and cell debris. Pelleted exosomes were collected after 90-min centrifuge at 100 000 gmax. In some experiments, exosomes were also purified using Exosome Isolation Reagent (Invitrogen). For blocking of exosome release from MDSCs, sorted MDSCs were treated with GW-4869 (10 μM) for 48 h in the presence of 1 ng/ml GM-CSF.
In vivo tumor growth, chemotherapy and metastatic assays Mice were killed for ethical reasons when they exhibited severe morbidity signs owing to overwhelming metastatic lesions (end point at 6-7 weeks) in compliance with IACUC regulations. Based on our preliminary data, seven mice per dose group for each treatment will have 94% power and can detect a mean difference of 2.8 between treatment groups at each time point with a subject variance of 1 after controlling the overall type-I error rate of 5% using analysis of variance. Mice were randomly divided into groups. Mice that died within 72 h after tumor cell injection were excluded from the evaluation. Tumors were measured every 3 days using calipers and calculated as 0.52 × length × width 2 . Lungs were fixed in buffered formalde-fresh solution (Fisher, Asheville, NC, USA) and stained with hematoxylin and eosin for counting metastatic nodules.
Tube-formation assay and adhesion assay Matrigel (BD Biosciences) was added to the wells of a 48-well plate in a volume of 120 μl and allowed to solidify at 37°C for 30 min. After the matrigel solidified, ECs (4 × 10 4 per 0.2-ml well of a 48-well plate) were seeded in RPMI medium with 1% FBS with or without 50 μg/ml MDSCderived exosomes at various concentrations for 16 h. Cell organization onto matrigel was analyzed using an inverted light microscope (Nikon, Tokyo, Japan). All tube-like structures were counted for each well; only closed networks of vessel-like tubes were counted. In some experiments, ECs were co-incubated with different sources of MDSCs (1:1 ratio, each 2 × 10 4 per 0.2-ml well of a 48-well plate). MDSCs were sorted from the lungs or tumors of tumor-bearing mice with or without chemotherapy treatment. The effect of MDSC-derived exosomes on adhesion of 4T1 tumor cells to ECs was evaluated. EC monolayers were pretreated for 24 h at 37°C in RPMI medium with 1% fetal calf serum with or without exosomes. 4T1 tumor cells (5 × 10 5 per well), labeled with CFSE (carboxyfluorescein succinimidyl ester), were added to the endothelial monolayer. The adhesion assay in static conditions was evaluated after 6 h. After washings, cells adherent to ECs were counted by fluorescence microscopy (magnification × 200) in 10 fields and expressed as mean ± s.e. m. of cells per field.
Angiogenic factor assay
The presence of proangiogenic/antiangiogenic factors in cell supernatants and cell lysates was assessed using the Proteome Profiler Antibody Array (R&D) specific for mouse angiogenesis. Sorted VEH-MDSCs or DOX-MDSCs from the lung (2 × 10 6 cells, obtained by pooling five lung) were plated in DMEM and 2% FBS, and after 5 days, their supernatants were collected and stored at -20°C until analysis.
Exosomal miR-126a and myeloid cell differentiation Bone marrow cells were harvested from the femurs and tibias of mice and sorted for progenitor cells (Lin − c-Kit + CD11b
− Gr-1 − cells). To assess the effects of MDSC-derived exosomes or miRNA on MDSC accumulation/DC differentiation, 1 × 10 6 enriched progenitor cells were placed into each well of 24-well plates for 5 days in 2-ml of RPMI supplemented with 10% FBS, 20 ng/ml GM-CSF and 10 ng/ml IL-4 in the presence of GNVs carrying mock, miR-126a inhibitor or miR-126a mimic.
Isolation and uptake of exosome and GNV trafficking in vivo
To isolate exosomes from cell culture medium, the cell culture supernatants were collected and purified by differential centrifugation using a previously described method. 53 To monitor exosome trafficking and uptake in vivo, exosomes or GNVs were labeled with the PKH26 red fluorescent dye using a commercially available kit (Sigma-Aldrich) and according to a previously described protocol. 54 Tumor-bearing mouse received 40 μg PKH26-labeled exosomes administered i.v. via the tail vein. Eighteen-to-24 h after injection, the mice were killed and the peripheral blood and liver, lung and spleen tissues were collected. Single-cell suspensions of each tissue were prepared in RPMI 1640 medium and subjected to FACS analysis. The percentages of cells containing exosomes or GNVs were determined by counting green fluorescent-positive cells.
Suppression assays
Naive CD4 + CD25 − CD62L + T cells were labeled with 5 mM CellTrace CFSE according to the manufacturer's instructions (Invitrogen) and stimulated with plate-bound anti-CD3 (5 μg/ml) and soluble CD28 (5 μg/ml) for 4 days in the presence or absence of exosomes (50 μg/ml) from MDSC isolated from 4T1 tumor-bearing mice, treated or not with DOX, at the following ratio, MDSC to T cell ratio = 1:2. After 4 days, cell proliferation was determined by measuring the dilution of CellTrace CFSE by flow cytometry after gating on the CD4 + cell populations. The level and number of IFN-γ-and CD4-producing cells in response to stimulation was evaluated by ELISA or FACS. miRNA mimic and hairpin inhibitor transfection MDSCs or bone marrow cells were cultured in six-well plates and transfected the following day. In all, 100 pmol miR-126a mimic or inhibitor encapsulated in GNV 46 was used. Cells were rested in exosome-free media, washed and co-cultured with T cells, as indicated, for 24-48 h. Oligonucleotides with random sequence served as negative controls for miRNA mimic or inhibitor.
Statistical analysis
Values are shown as s.e.m. except otherwise indicated. Comparison of multiple experimental groups was performed by two-way analysis of variance test. A t-test was used to compare the means of two groups. P-values of o0.05 were considered to be statistically significant. Sample sizes are calculated to allow significance to be reached.
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